Health Care Equipment

Alphatec

Alphatec released FY2026 Q1 earnings on May 5 After-Market EST, actual revenue USD 192.11 M (forecast USD 196.6 M), actual EPS USD -0.22 (forecast USD -0.25)

Alphatec to Release FY2026 Q1 Earnings on May 5 After-Market EST, Forecast Revenue USD 196.6 M, EPS USD -0.25

Alphatec released FY2025 Annual Earnings on February 24 After-Market (EST), Actual Revenue: USD 764.16 M (Forecast: USD 763.54 M), Actual EPS: USD -0.9553 (Forecast: USD -0.946)

Alphatec released FY2025 Q4 earnings on February 24 After-Market EST, actual revenue USD 212.93 M (forecast USD 212.24 M), actual EPS USD -0.1474 (forecast USD -0.136)

Alphatec to Release FY2025 Q4 Earnings on February 24, 2026 After-Market EST, Forecast Revenue USD 212.27 M, EPS USD -0.136

Alphatek Holdings Reveals 2026 Growth Strategy

AlphaTech Holdings Secures US Exclusive Sales Rights for OsteoAdapt

Alphatec Holdings Inc Reports 2025 Preliminary Results and Outlines 2026 Revenue Outlook

AlphaTech Holdings CEO Patrick Myers Sells Common Stock

AlphaTech Holdings COO Scott Lish Reports Sale of Common Stock

Director David R. Pelizzon Disposes of Alphatech Holdings Corporation Common Stock

Canaccord Genuity analyst maintains buy rating on Alphatek Holding

AlphaTech Holdings COO Scott Lish Reports Disposition of Common Stock

Morgan Stanley Raises AlphaTek Holding's Target Price to $21.00

Alphatec Holdings Director Sells Company's Common Stock

David Saxon Raises AlphaTech Holdings' Target Price to $22 and Assigns Buy Rating

Alphatec released FY2025 Q3 earnings on October 30 After-Market (EST), actual revenue USD 196.5 M (forecast USD 182.63 M), actual EPS USD -0.1887 (forecast USD -0.1633)

Alphatec released FY2025 9 Months Earnings on October 30 After-Market EST, Actual Revenue: USD 551.23 M, Actual EPS: USD -0.8169

AlphaTech Holdings Reports Q3 Revenue Beat

Alphatec to Release FY2025 Q3 Earnings on October 30 After-Market EST, Forecast Revenue USD 182.78 M, EPS USD -0.1633

OPTIMI HEALTH CORP

HCW Biologics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Micware

Silexion Therapeutics

GCL Global

EMMIS ACQUISITION CORP. ORD USD0.0001 (S/R 12/09/2030)

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

ATEC

IBBQ

Kirby McInerney LLP is investigating potential claims against Alphatec Holdings, Inc. regarding possible violations of federal securities laws. Following a disappointing first quarter report on May 5, 2026, where Alphatec's revenue fell short of expectations, the company's stock price dropped by approximately 32%. The investigation aims to determine if legal claims can be filed. Investors with information or interest are encouraged to contact the law firm.

MorningStar

iShares US Medical Devices

SPDR S&P Health Equip

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

ATEC INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Alphatec Holdings, Inc.

Alphatec Holdings, Inc. (NASDAQ:ATEC) saw its stock price rise by 7.4% to $8.2290 during trading, despite a 41% decline in volume. Analysts have mixed views, with price targets ranging from $11.00 to $24.00. The company reported a quarterly revenue of $192.11 million but missed EPS estimates. Insider trading activity has seen significant share sales, and institutional investors have adjusted their positions in the company.

Market Beat

Barclays

Wells Fargo

Abrdn plc

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

Alphatec (NASDAQ:ATEC) Stock Price Up 7.4%  - Here's Why

Alphatec Holdings, Inc. (NASDAQ:ATEC) has received an average rating of "Moderate Buy" from twelve research firms. One analyst rated it as a sell, one as hold, and ten as buy. The average target price is $18.58. Recent reports show price target reductions from various firms, with notable decreases from Needham & Company and Wells Fargo. Insider trading activity includes significant sales by executives. Hedge funds have also adjusted their holdings, with 66.35% of shares owned by institutional investors. ATEC stock opened at $7.74, with a market cap of $1.19 billion and a negative EPS of ($0.22).

Piper Sandler Cos

PNC Financial Services

Alphatec Holdings, Inc. (NASDAQ:ATEC) Given Average Rating of "Moderate Buy" by Brokerages

Alphatec Director Valentine Keith purchased shares worth over $996K, acquiring 56,153 shares at $7.49 each on May 7, 2026, 43,847 shares at $7.54 each on May 8, and 35,000 shares at $7.00 each on May 11. Following these transactions, Keith now owns a total of 232,271 shares of Alphatec Holdings common stock.

TradingView

Alphatec Director Purchased Shares Worth Over $996K

Stifel Nicolaus analyst Thomas Stephan maintained a Buy rating on Alphatec Holdings (ATEC) with a price target of $16.00. The stock closed at $7.52. The analyst has a 5.1% average return and a 40.91% success rate. The overall analyst consensus for Alphatec is a Strong Buy, with an average price target of $18.91, indicating a potential upside of 151.46%. H.C. Wainwright also reiterated a Buy rating with a $24.00 price target.

Tip Ranks

Stifel Financial

TransMedics

Bausch + Lomb

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

Stifel Nicolaus Sticks to Their Buy Rating for Alphatec Holdings (ATEC)

Yesterday's closing, Alphatec Holdings (ATEC.US) continued its weak trend, with the daily MACD forming a bearish crossover signal below the zero axis. This signal usually indicates that the short-term corrective rally is difficult to sustain, and the bearish forces are regaining strength after a brief respite from the bulls. The trading volume was approximately $90.76 million, which is considered medium to high in the medical device sector, indicating a decent level of market activity for the stock, but the continued price weakness suggests that selling pressure is dominant. The stock price is operating below the short-term moving averages, and any rebound to the vicinity of the moving averages is met with resistance, leading to a retreat of the bullish front. On the news front, the medical device sector has recently lacked significant positive catalysts. ZTS experienced a drop of over 21% yesterday; although it belongs to the animal health sector rather than the orthopedic device track, the sharp fluctuations of major medical stocks often trigger sector-wide risk-averse sentiment. Additionally, the Federal Reserve's stance on maintaining high interest rates also indirectly pressures medical device companies—these growth-oriented companies often rely on substantial R&D investment and financing support, and a tight interest rate environment means rising capital costs and valuation pressure. Regarding employment market data, the initial jobless claims were lower than expected, indicating that the labor market remains resilient, making it difficult to open a rate cut window in the short term, which constrains the valuation recovery of growth-oriented medical companies. From a technical perspective, the secondary death cross below the MACD zero axis is a signal that reinforces the bearish pattern, with clear resistance from the moving averages. In terms of volume, the performance is stable, with neither panic selling nor active buying intervention, placing the market in a weak equilibrium state

Technical Forecast

Zoetis

Pre-market trend | Alphatec Holdings (ATEC) encounters selling pressure again below the zero axis on May 7, is the rebound of medical device stocks hindered?

Lisanti Capital Growth has completely exited its position in Alphatec, selling 372,407 shares for approximately $5.42 million. This sale reflects a significant decrease in the fund's assets, with Alphatec's stock now representing 0% of its 13F reportable assets under management. The stock has underperformed, down 42.6% over the past year, and the company has faced challenges, including missed revenue expectations and a cut in full-year guidance. Investors are advised to consider other stocks, as Alphatec was not included in a recent list of top investment recommendations.

nasdaq

Five Below

Patterson-UTI Energy

Carpenter Tech

Modine Manufacturing

BrightSpring Health Services

S&P 500

Netflix

NVIDIA

BrightSpring Health Services - Unit

NVIDIA Corporation

Lisanti Capital Dumps $5.4 Million Alphatec Stake as Medical Device Maker Struggles

Wells Fargo & Company has lowered its price target for Alphatec (NASDAQ: ATEC) from $28.00 to $14.00 while maintaining an "overweight" rating. This suggests a potential upside of 83.37% from the previous close. Other analysts have also adjusted their ratings, with Canaccord Genuity setting a target of $23.00 and HC Wainwright at $24.00. Alphatec's stock recently traded at $7.64, with a market cap of $1.17 billion. The company reported a revenue of $192.11 million for the last quarter, missing estimates.

Lisata Therapeutics

Alphatec (NASDAQ:ATEC) Given New $14.00 Price Target at Wells Fargo & Company

Ademi LLP is investigating potential securities fraud claims against Alphatec Holdings, Inc. (NASDAQ: ATEC) due to possible inaccuracies in the company's financial statements and business operations. The investigation follows Alphatec's acknowledgment of operational issues with its EOS business. Shareholders can join the investigation or obtain more information at no cost.

prnewswire

18:09 ETShareholder Alert: Ademi LLP Investigates Claims of Securities Fraud against Alphatec Holdings, Inc.

Alphatec(ATEC.US)